Utilizing an automation-on-demand analytical tool for cancer immunotherapy

At the turn of the century, adoptive cell therapies (ACT) using autologous peripheral lymphocytes or tumor-infiltrating lymphocytes (TILs) after stimulation and expansion by lymphokines have been widely attempted in clinical settings. Macrophages and Natural Killer (NK) cells are the primary innate cell populations within the Tumor Microenvironment (TME) exhibiting different cytotoxic properties compared to T-cells. Macrophages perform multiple functions, including phagocytosis, immunomodulation, TME remodeling, and antigen-presentation, whereas adoptive technologies based on cutting-edge NK cells potentially eliminate tumor cells via natural cytotoxicity receptors and/or through CD16-mediated antibody-dependent cell-mediated cytotoxicity (ADCC).

For preclinical immunotherapy drug development laboratories, recurring workflows are associated with antibody or cell characterization techniques such as flow cytometry. These workflows often require rethinking the analytical process from the sample preparation end.

Come join us as Christoph Eberle, PhD (Charles River Laboratories) takes us through a series of case studies involving Laminar Wash™ technology adoption to refine the analytical armamentarium associated with cancer immunotherapy.

Attend this webinar to discover:

• Techniques involving side-by-side comparison of murine and human antibody titrations, targeting NK and myeloid cells
• Methods to successfully adapt phospho-staining of HDAC proteins for flow cytometric readouts
• Insights in recovering thawed lymphocytes when determining multi-lab site deployment

Christoph Eberle

Principal Scientist III, Charles River Laboratories

Christoph S. Eberle, PhD, MICR, FRSPH is a Principal Scientist III who has established and overseen the flow cytometry core at the Charles River Discovery site in Worcester, MA since he joined in 2017.

He directs immunophenotyping of tissue samples collected from various mouse models to include T-cell isolations for adoptive transfers and immunoassay development on various protein detection platforms.

Watch now

SPEAKERS

Christoph Eberle

Principal Scientist III, Charles River Laboratories

You might also like

Process in the product: a new analytical tool for AAV production optimization and monitoring

Blaž Bakalar, Ivana Petrović Koshmak

19 November

Watch

Increased productivity in the analytical testing of AAV titers with an automated immunoassay platform

E Feeley, M Gianneli, J Venet

17 April

Watch

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Qingrui You, Peiqing Zhang

29 October

Watch

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Qingrui You, Peiqing Zhang

26 November

Watch

Preparing for success in gene therapy analytical development

Y Zhi, J Li, A Castillo

9 October

Watch